Eltrombopag olamine and Malignant neoplasm progression - a phase IV clinical study of FDA data

Summary:

Malignant neoplasm progression is reported as a side effect among people who take Eltrombopag olamine (eltrombopag olamine), especially for people who are male, 60+ old, have been taking the drug for 5 - 10 years also take Cyclosporine, and have Aplastic anemia.

The phase IV clinical study analyzes which people have Malignant neoplasm progression when taking Eltrombopag olamine. It is created by eHealthMe based on reports of 3,901 people who have side effects when taking Eltrombopag olamine from the FDA, and is updated regularly.

What is Eltrombopag olamine?

Eltrombopag olamine has active ingredients of eltrombopag olamine. eHealthMe is studying from 3,901 Eltrombopag olamine users. Check the latest studies of Eltrombopag olamine.

What is Malignant neoplasm progression?

Malignant neoplasm progression (cancer tumour came back) is found to be associated with 1,507 drugs and 1,635 conditions by eHealthMe. Check the latest studies of Malignant neoplasm progression.

On Jul, 25, 2026

3,901 people reported to have side effects when taking Eltrombopag olamine.
Among them, 20 people (0.51%) have Malignant neoplasm progression.

Could Eltrombopag olamine cause Malignant neoplasm progression?

Among these 20 people:

How long have people been on Eltrombopag olamine when they have Malignant neoplasm progression? *

What is the gender of people who have Malignant neoplasm progression when taking Eltrombopag olamine? *

female: 43.75 %
male: 56.25 %

What is the age of people who have Malignant neoplasm progression when taking Eltrombopag olamine? *

What are other drugs people take besides Eltrombopag olamine? *

What are other side effects people have besides Malignant neoplasm progression? *

Thrombosis (formation of a blood clot inside a blood vessel): 8 people, 40.00%
Disease Progression: 7 people, 35.00%
Death: 7 people, 35.00%
Thrombocytopenia (decrease of platelets in blood): 6 people, 30.00%
Disease Recurrence: 4 people, 20.00%
Ventricular Fibrillation (abnormally irregular heart rhythm): 2 people, 10.00%
Hypokalemia (low potassium): 2 people, 10.00%
Cytokine Release Syndrome (immediate complication occurring with the use of anti-t cell antibody infusions): 2 people, 10.00%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 2 people, 10.00%
Renal Disorder (kidney disease): 1 person, 5.00%

What are the existing conditions these people have? *

Prostate Cancer: 2 people, 10.00%
Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 2 people, 10.00%
Aplastic Anemia: 2 people, 10.00%
Pollakiuria (abnormally frequent passage of relatively small quantities or urine): 1 person, 5.00%
Paroxysmal Nocturnal Haemoglobinuria (haemoglobin in the urine): 1 person, 5.00%
Multiple Myeloma (cancer of the plasma cells): 1 person, 5.00%
Insomnia (sleeplessness): 1 person, 5.00%
Diabetes: 1 person, 5.00%
Constipation: 1 person, 5.00%

* Approximation only. Some reports may have incomplete information.

Do you take Eltrombopag olamine and have Malignant neoplasm progression?

- Check whether Malignant neoplasm progression is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Eltrombopag olamine:

Eltrombopag olamine (3,901 reports)

Browse all side effects of Eltrombopag olamine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Malignant neoplasm progression:

Malignant neoplasm progression (1,508 drugs)

Browse all the conditions that are associated with Malignant neoplasm progression:

Malignant neoplasm progression (1,635 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on eltrombopag olamine (the active ingredients of Eltrombopag olamine) and Eltrombopag olamine (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.